Gingko biloba extract improves the lipid profile, inflammatory markers, leptin level and the antioxidant status of T2DM patients poorly responding to metformin: A double- blind, randomized, placebo-controlled trial
Abstract The present study aims to evaluate the effects of Ginkgo biloba (GKB) extract as “add- on” therapy with metformin on the lipid profile, inflammatory markers, leptin and the total antioxidant capacity (TAOC) of patients with type 2 diabetes mellitus (T2DM). It is a multi- center, randomized,...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Universidade de São Paulo
2022-07-01
|
| Series: | Brazilian Journal of Pharmaceutical Sciences |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502022000100612&tlng=en |
| _version_ | 1811323758569324544 |
|---|---|
| author | Saad Abdulrahman Hussain Tavga Ahmed Aziz Taha Othman Mahwi Zheen Aorahman Ahmed |
| author_facet | Saad Abdulrahman Hussain Tavga Ahmed Aziz Taha Othman Mahwi Zheen Aorahman Ahmed |
| author_sort | Saad Abdulrahman Hussain |
| collection | DOAJ |
| description | Abstract The present study aims to evaluate the effects of Ginkgo biloba (GKB) extract as “add- on” therapy with metformin on the lipid profile, inflammatory markers, leptin and the total antioxidant capacity (TAOC) of patients with type 2 diabetes mellitus (T2DM). It is a multi- center, randomized, placebo-controlled double-blinded clinical study. Sixty patients were allocated into two groups: control and treatment groups; they received orally either 120 mg starch/capsule or 120mg GKB/capsule, respectively as an adjuvant with metformin for 90 days. Blood samples were obtained at zero time and after 90 days. The blood was utilized for analysis of the lipid profile, inflammatory markers, leptin, and TAOC. The GKB extract produced a significant decrease in the levels of TG, LDL-c, and CRP, with a significant increase in HDL-c compared to baseline values. There were no significant changes reported in the placebo-treated group. It also produced a significant decrease in the concentrations of IL-6, TNF-α, and leptin compared to baseline values and placebo-treated groups with a significant increase in TAOC compared to baseline values. In conclusion, GKB extract, as an adjuvant with metformin, decreases inflammatory mediators, leptin level and improves the antioxidant status and lipid profile of T2DM patients improperly managed with metformin. |
| first_indexed | 2024-04-13T14:01:30Z |
| format | Article |
| id | doaj.art-88e46597d61f49b6b4aa82f96a8bf14b |
| institution | Directory Open Access Journal |
| issn | 2175-9790 |
| language | English |
| last_indexed | 2024-04-13T14:01:30Z |
| publishDate | 2022-07-01 |
| publisher | Universidade de São Paulo |
| record_format | Article |
| series | Brazilian Journal of Pharmaceutical Sciences |
| spelling | doaj.art-88e46597d61f49b6b4aa82f96a8bf14b2022-12-22T02:44:02ZengUniversidade de São PauloBrazilian Journal of Pharmaceutical Sciences2175-97902022-07-015810.1590/s2175-97902022e19516Gingko biloba extract improves the lipid profile, inflammatory markers, leptin level and the antioxidant status of T2DM patients poorly responding to metformin: A double- blind, randomized, placebo-controlled trialSaad Abdulrahman Hussainhttps://orcid.org/0000-0002-1909-417XTavga Ahmed AzizTaha Othman MahwiZheen Aorahman AhmedAbstract The present study aims to evaluate the effects of Ginkgo biloba (GKB) extract as “add- on” therapy with metformin on the lipid profile, inflammatory markers, leptin and the total antioxidant capacity (TAOC) of patients with type 2 diabetes mellitus (T2DM). It is a multi- center, randomized, placebo-controlled double-blinded clinical study. Sixty patients were allocated into two groups: control and treatment groups; they received orally either 120 mg starch/capsule or 120mg GKB/capsule, respectively as an adjuvant with metformin for 90 days. Blood samples were obtained at zero time and after 90 days. The blood was utilized for analysis of the lipid profile, inflammatory markers, leptin, and TAOC. The GKB extract produced a significant decrease in the levels of TG, LDL-c, and CRP, with a significant increase in HDL-c compared to baseline values. There were no significant changes reported in the placebo-treated group. It also produced a significant decrease in the concentrations of IL-6, TNF-α, and leptin compared to baseline values and placebo-treated groups with a significant increase in TAOC compared to baseline values. In conclusion, GKB extract, as an adjuvant with metformin, decreases inflammatory mediators, leptin level and improves the antioxidant status and lipid profile of T2DM patients improperly managed with metformin.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502022000100612&tlng=enGinkgo bilobaUncontrolled T2DMInflammatory markersLeptinAntioxidant status |
| spellingShingle | Saad Abdulrahman Hussain Tavga Ahmed Aziz Taha Othman Mahwi Zheen Aorahman Ahmed Gingko biloba extract improves the lipid profile, inflammatory markers, leptin level and the antioxidant status of T2DM patients poorly responding to metformin: A double- blind, randomized, placebo-controlled trial Brazilian Journal of Pharmaceutical Sciences Ginkgo biloba Uncontrolled T2DM Inflammatory markers Leptin Antioxidant status |
| title | Gingko biloba extract improves the lipid profile, inflammatory markers, leptin level and the antioxidant status of T2DM patients poorly responding to metformin: A double- blind, randomized, placebo-controlled trial |
| title_full | Gingko biloba extract improves the lipid profile, inflammatory markers, leptin level and the antioxidant status of T2DM patients poorly responding to metformin: A double- blind, randomized, placebo-controlled trial |
| title_fullStr | Gingko biloba extract improves the lipid profile, inflammatory markers, leptin level and the antioxidant status of T2DM patients poorly responding to metformin: A double- blind, randomized, placebo-controlled trial |
| title_full_unstemmed | Gingko biloba extract improves the lipid profile, inflammatory markers, leptin level and the antioxidant status of T2DM patients poorly responding to metformin: A double- blind, randomized, placebo-controlled trial |
| title_short | Gingko biloba extract improves the lipid profile, inflammatory markers, leptin level and the antioxidant status of T2DM patients poorly responding to metformin: A double- blind, randomized, placebo-controlled trial |
| title_sort | gingko biloba extract improves the lipid profile inflammatory markers leptin level and the antioxidant status of t2dm patients poorly responding to metformin a double blind randomized placebo controlled trial |
| topic | Ginkgo biloba Uncontrolled T2DM Inflammatory markers Leptin Antioxidant status |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502022000100612&tlng=en |
| work_keys_str_mv | AT saadabdulrahmanhussain gingkobilobaextractimprovesthelipidprofileinflammatorymarkersleptinlevelandtheantioxidantstatusoft2dmpatientspoorlyrespondingtometforminadoubleblindrandomizedplacebocontrolledtrial AT tavgaahmedaziz gingkobilobaextractimprovesthelipidprofileinflammatorymarkersleptinlevelandtheantioxidantstatusoft2dmpatientspoorlyrespondingtometforminadoubleblindrandomizedplacebocontrolledtrial AT tahaothmanmahwi gingkobilobaextractimprovesthelipidprofileinflammatorymarkersleptinlevelandtheantioxidantstatusoft2dmpatientspoorlyrespondingtometforminadoubleblindrandomizedplacebocontrolledtrial AT zheenaorahmanahmed gingkobilobaextractimprovesthelipidprofileinflammatorymarkersleptinlevelandtheantioxidantstatusoft2dmpatientspoorlyrespondingtometforminadoubleblindrandomizedplacebocontrolledtrial |